Improved Tumor Infiltration and Immunomodulation for Tumor Therapy: A Pathway Based on Tetrahedral Framework Nucleic Acids Coupled Bacterial Nanocells
Source abstract
Abstract
Growing evidence indicates that the tumor microenvironment (TME) can be combined with other therapeutic modalities, including cytotoxic chemotherapy and targeted therapies, to produce unanticipated results in oncology treatment. Here, we proposed a novel bacterial nanomaterial capable of targeting peritumoral biofilm and modulating TME. It was based on tetrahedral framework nucleic acids (T) that were chemically attached to aptamer AS1411 and 5-fluorouracil (AT5). Additionally, the oral pathogenic bacterium Streptococcus mutans (S.m) was employed as a biocarrier for synergetic biofilm targeting and immunomodulation. In this article, the effect of AT5-coupled S.m-derived nanocells (S.m-AT5) was investigated in vitro and in vivo. Due to bacteria aggregation in the tumor-specific biofilm, these nanocells released greater medication concentrations. Furthermore, they exerted an immunomodulatory effect by stimulating the maturation of dendritic cells (DCs) and regulation of T cells. This chemo-immunostimulation combination has a powerful antitumor impact. It may also be an advanced approach for boosting the survival rate of cancer patients.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Research and Treatments · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China
Funding
Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · Sichuan Province Youth Science and Technology Innovation Team · West China School/Hospital of Stomatology, Sichuan University
References (54)
Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.1016/S0140-6736(20)30752-210.1016/S0140-6736(20)30752-2 ↗
3. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
4. 10.1158/0008-5472.CAN-07-661110.1158/0008-5472.CAN-07-6611 ↗
5. 10.1021/acsnano.5b0452010.1021/acsnano.5b04520 ↗
6. Matsumoto H. · Anticancer Res. · 2015 · 35 · 6193
7. 10.1021/nn300296p10.1021/nn300296p ↗
8. 10.1016/j.biopha.2018.05.12410.1016/j.biopha.2018.05.124 ↗
9. 10.1124/mol.109.05594710.1124/mol.109.055947 ↗
10. 10.1021/acsami.7b1332810.1021/acsami.7b13328 ↗
11. 10.1002/adma.20220251310.1002/adma.202202513 ↗
12. 10.1021/acsnano.1c0962610.1021/acsnano.1c09626 ↗
13. 10.1002/adfm.20220458710.1002/adfm.202204587 ↗
14. 10.1002/advs.20220205810.1002/advs.202202058 ↗
15. 10.1021/acs.nanolett.2c0002510.1021/acs.nanolett.2c00025 ↗
16. 10.1002/adma.20220428710.1002/adma.202204287 ↗
17. 10.1002/adma.20220173110.1002/adma.202201731 ↗
18. 10.1021/acsami.9b0344910.1021/acsami.9b03449 ↗
19. 10.1002/adma.20180588810.1002/adma.201805888 ↗
20. 10.1002/jgm.308810.1002/jgm.3088 ↗
21. 10.1016/j.biomaterials.2017.10.02410.1016/j.biomaterials.2017.10.024 ↗
22. 10.1038/s41467-020-16967-210.1038/s41467-020-16967-2 ↗
23. 10.1016/j.cell.2019.07.00810.1016/j.cell.2019.07.008 ↗
24. 10.1186/1471-2180-12-14410.1186/1471-2180-12-144 ↗
25. 10.1002/adfm.20190662310.1002/adfm.201906623 ↗
26. 10.1002/adma.20200737910.1002/adma.202007379 ↗
27. 10.1016/j.ccell.2020.02.00110.1016/j.ccell.2020.02.001 ↗
28. 10.1016/j.biomaterials.2018.09.04210.1016/j.biomaterials.2018.09.042 ↗
29. 10.1128/microbiolspec.GPP3-0051-201810.1128/microbiolspec.GPP3-0051-2018 ↗
30. 10.1007/s40820-020-0409-310.1007/s40820-020-0409-3 ↗
31. 10.1038/s41368-022-00171-710.1038/s41368-022-00171-7 ↗
32. 10.3389/fcell.2019.0005210.3389/fcell.2019.00052 ↗
33. 10.3389/fmicb.2019.0224110.3389/fmicb.2019.02241 ↗
34. 10.1016/j.cellsig.2012.06.00310.1016/j.cellsig.2012.06.003 ↗
35. Meng L. Y. · Asian Pac J. Cancer Prev. · 2011 · 12 · 3483
36. 10.1007/s10495-012-0791-510.1007/s10495-012-0791-5 ↗
37. 10.1097/MD.000000000001057510.1097/MD.0000000000010575 ↗
38. 10.1038/cddis.2017.22010.1038/cddis.2017.220 ↗
39. 10.1016/j.toxlet.2018.04.03310.1016/j.toxlet.2018.04.033 ↗
40. 10.1074/jbc.273.25.1554010.1074/jbc.273.25.15540 ↗
41. 10.1111/j.1365-2605.2011.01153.x10.1111/j.1365-2605.2011.01153.x ↗
42. 10.1126/science.117054010.1126/science.1170540 ↗
43. 10.1038/s41577-019-0210-z10.1038/s41577-019-0210-z ↗
44. 10.1038/s41586-020-2134-y10.1038/s41586-020-2134-y ↗
45. 10.1016/j.immuni.2015.05.01810.1016/j.immuni.2015.05.018 ↗
46. 10.1038/ni.386810.1038/ni.3868 ↗
47. 10.1038/s41586-019-1836-510.1038/s41586-019-1836-5 ↗
48. 10.1155/2016/894126010.1155/2016/8941260 ↗
49. 10.1016/j.immuni.2011.07.01010.1016/j.immuni.2011.07.010 ↗
50. 10.3389/fimmu.2018.0269210.3389/fimmu.2018.02692 ↗
51. 10.1111/imm.1317810.1111/imm.13178 ↗
52. 10.1002/cyto.a.2372410.1002/cyto.a.23724 ↗
53. 10.1016/j.immuni.2019.01.02010.1016/j.immuni.2019.01.020 ↗
54. 10.1182/blood-2018-11-84454810.1182/blood-2018-11-844548 ↗